Krystexxa
NDC 54396-801
Product Information
Krystexxa is a BLA-approved product labeled by Savient Pharmaceuticals, Inc.. Pegloticase is used to treat gout which has not responded to the usual treatments. It is supplied as a product. This product entry covers the primary NDC 54396-801 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 54396-801?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PEGLOTICASE (UNII: R581OT55EA)
- PEGLOTICASE (UNII: R581OT55EA) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM PHOSPHATE, DIBASIC, DIHYDRATE (UNII: 94255I6E2T)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1011653 - pegloticase 8 MG in 1 ML Injection
- RxCUI: 1011653 - 1 ML pegloticase 8 MG/ML Injection
- RxCUI: 1011653 - pegloticase (as uricase protein) 8 MG per 1 ML Injection
- RxCUI: 1011653 - pegloticase 8 MG per 1 ML Injection
- RxCUI: 1011657 - Krystexxa 8 MG in 1 ML Injection
* Please review the full disclaimer at the bottom of this page.